Industry Updates for the Psychedelics World | Page 28 of 35

Psychedelics News

Industry

4 May 2022

New Study Shows Positive Results for Compass Pathways’ COMP360

COMPASS Pathways released recent results from two studies using the company's COMP360 compound....

By Jason Najum

Industry

29 Apr 2022

Field Trip to Split Into Two Independent Public Companies

Big news as Field Trip Health splits its operations into two separate publicly-traded companies....

By Microdose

Industry

28 Apr 2022

TRYP Therapeutics Doses First Patients in Phase 2 Psilocybin Trial

TRYP has started a Phase 2 trial to determine efficacy of psilocybin psychotherapy for the treatment of Binge Eating Disorder...

By Microdose

Industry

27 Apr 2022

Phyto Partners and Ambria Capital Launch Neurowellness VC Fund

Phyto Partners has partnered with Ambria Capital to launch a fund focused on businesses operating in and around neurowellness and brain health and the use of psychedelic compounds....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

21 Apr 2022

Cybin Announces Partnership for CYB-003 Trial

Cybin has announced a partnership with a leading CRO (Clinilabs) to help them with their upcoming trial for lead candidate compound CYB-003...

By Jason Najum

Industry

20 Apr 2022

Irwin Naturals Acquires Chain of Ketamine Clinics

Irwin Naturals announced an acquisition agreement with KHC Capital Group (“Ketamine Health Centers”) and their chain of five ketamine treatment clinics in Florida....

By Microdose

Events, Industry

18 Apr 2022

PsyCap Recap: Clearmind Medicine

With dozens of companies racing to drive classic psychedelics through clinical trials, or spending years and untold millions developing next-generation versions of these well-known molecules, Clearmind could have its own...

By Microdose

Industry

14 Apr 2022

MindMed to Announce Results for LSD Trial

Today we learned that MindMed collaborators from the University Hospital Basel will present results from their Phase 2 clinical trial of LSD in the treatment of anxiety disorders....

By Jason Najum

Industry

13 Apr 2022

Cybin Announces Positive Data on CYB004 DMT

Delivery of CYB004 via inhalation showed significant advantages over intravenously administered dimethyltryptamine (“IV DMT”) in preclinical studies...

By Microdose

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result